Condition Directory

Prostate Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Prostate Cancer. Browse Prostate Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 16, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

901

Shown on this page

Current sort

How Prostate Cancer studies are organized in the registry

Prostate cancer studies are organized around disease-state vocabulary more than most cancers: “castration-resistant” (CRPC), “hormone-sensitive,” and “biochemical recurrence” mark distinct study populations and appear directly in listings. Active-surveillance research is typically registered as observational, so the study-type filter separates it cleanly.

Terms that often appear in related listings

castration-resistant CRPC hormone-sensitive biochemical recurrence

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 421–432 of 901 matching trials for Prostate Cancer.

Indexed local directory records.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Open in full search

Conditions: Advanced Solid Tumor, Breast Cancer, Homologous Recombination Deficiency, Metastatic Solid Tumor, Ovarian Cancer, Pancreas Cancer, Prostate Cancer
Interventions: MOMA-313, Olaparib; Drug
Lead sponsor: MOMA Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Goodyear, Arizona • La Jolla, California • San Francisco, California + 8 more

Conditions: Prostate Cancer, Radiation Toxicity, Urinary Complication
Interventions: Lisinopril Tablets; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: BET Bromodomain Inhibitor ZEN-3694, Enzalutamide, Pembrolizumab; Drug · Biological
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older · Male only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 3
States / cities: San Francisco, California • Evergreen Park, Illinois • Ann Arbor, Michigan

Conditions: Adrenocortical Carcinoma, Genitourinary Cancer, High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma, Non-adenocarcinoma Prostate Cancer, Non-urothelial Bladder, Non-urothelial Upper Tract, Penile Cancer, Refractory Germ-cell
Interventions: Ipilimumab, Nivolumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 6
States / cities: La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: Hypogonadism, Male, Prostate Cancer
Interventions: Testosterone cypionate; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Androgen Axis Suppression, Prostate Cancer, Prostatectomy
Interventions: Androgen Deprivation Therapy, Apalutamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: Gilbert, Arizona • Chicago, Illinois • Kansas City, Kansas + 3 more

Conditions: Prostate Cancer
Interventions: Standard of Care Regimen, Telmisartan; Other · Drug
Lead sponsor: Tyler J Curiel; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Abiraterone Acetate/Niraparib, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Prednisone; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Interventions: Biopsy, Bone Scan, Cystoscopy, Digital Rectal Examination, MRI-Guided Transurethral Ultrasound Ablation, Multiparametric Magnetic Resonance Imaging, PSMA PET Scan, Questionnaire Administration; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: 177Lu-TLX591, Abiraterone, Docetaxel, Enzalutamide; Drug
Lead sponsor: Telix Pharmaceuticals (Innovations) Pty Limited; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: Orange, California • Miami, Florida • Glen Burnie, Maryland + 6 more

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Dual X-ray Absorptiometry, Etoposide, Gallium Ga 68-PSMA-617, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radioconjugate, Single Photon Emission Computed Tomography, Testosterone Cypionate; Procedure · Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

About this Prostate Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Prostate Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Prostate Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Prostate Cancer clinical trials

How Prostate Cancer studies are organized in the registry

Filter and sort this condition

Stored official records

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Telmisartan in Prostate Cancer

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

A Study of Telemedicine Shared Medical Appointments (SMAs) Versus Individual Telemedicine Visits for People With Prostate Cancer

About this Prostate Cancer clinical trials directory page